Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
Filed with NSE · ISIN INE044A01028 ·
6ix is reading this filing.
View original source (NSE India)Sun Pharmaceutical Industries Limited on 6ix
Story so far
Earlier from Sun Pharmaceutical Industries
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
- New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
- Sun Pharmaceutical Industries Limited Press Release Sep 28 2026
- Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries